In light of the mTOR pathway’s upregulation observed in numerous chemoresistant cancers, sirolimus (rapamycin), a first-class mTOR inhibitor, has been revealed to augment apoptosis in human osteosarcoma cells and enhance their responsiveness to anticancer drugs, potentially through the regulation of miRNAs. Here, MTOR is linked to osteosarcoma.